Please tell us about your clinical experience. How many patients with migraines do you see on a yearly basis? What is the standard of care, and how is Nurtec ODT fitting in this space?

How many patients achieve good outcomes with standard of care medication? What side-effects are associated with standard of care drugs?

How often do people end up not getting good control of migraines and wanting to try out new medication? Is CGRP medication seen as a last-to-try option?

Can you talk to us more about the potential of monoclonal antibodies and small-molecule antagonists that target CGRP or its receptor and the impact it’s having on migraine management?

Since 2018, the FDA has approved 6 drugs that block either CGRP or its receptor. Can you tell us which are the most successful in your practice, and the reasons why?

In large, it’s been reported that CGRP-targeted drugs are similarly effective. In those who take them to prevent migraine, they almost entirely cease attacks for about 25% of people and another 50% or so report moderate improvement, with fewer attacks, and the rest don’t respond at all. What differentiation have you seen between available drugs, in those aspects?

Biohaven reports that its drug is the only one of the CGRP drugs to demonstrate efficacy in both the acute and preventive treatment of migraine. How important is this aspect in deciding what’s best for the patients?

How valid are the concerns that because CGRP is a potent dilator of blood vessels, blocking it might raise the long-term risk of stroke or heart attack?